AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03008889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Participants will start with taking 900mg of NAC once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63.
Study NCT03008889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will start with taking 900mg of the placebo once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events. The dosing for the placebo will increase in the same fashion as the active treatment.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63.
Study NCT03131258 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Donor Nephrectomy
Description: 48 Donor Nephrectomy Patients
Study NCT01191957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulphan plus Cyclophosphamide
Description: I.V. Bu (Busilvex), 12.8 mg/kg:~Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest~Followed by:~Cyclophosphamide, 120 mg/kg iv:~Day -4: 60 mg/kg Day -3: 60 mg/kg
Study NCT01191957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulphan plus Fludarabine
Description: I.V. Bu (Busilvex), 12.8 mg/kg:~Day -6: 0.8 mg/kg/dose x 4 doses Day -5: 0.8 mg/kg/dose x 4 doses Day -4: 0.8 mg/kg/dose x 4 doses Day -3: 0.8 mg/kg/dose x 4 doses plus:~Fludarabine, 4 x 40 mg/m² iv:~Day -6: 40 mg/m² Day -5: 40 mg/m² Day -4: 40 mg/m² Day -3: 40 mg/m²
Study NCT04525560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEG-ELS-S
Description: 2/3 dose of PEG-ELS was taken orally from the evening on the day before colonoscopy, and the remaining 1/3 dose of PEG-ELS was orally administered in the morning of the next day.
Study NCT04525560 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEG-ELS-L
Description: PEG-ELS is given orally on the day before colonoscopy, which is divided into 10-12 portions and taken one portion every hour. If half of the total amount is not completed at afternoon ward round the day before colonoscopy, nasogastric feeding is recommended.
Study NCT03873233 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aisys Carestation ventilator and normal endotracheal tube
Description: Fraction of Inspired Oxygen (FIO2) 0.3 End Expiratory Pressure (EEP) at +5 cm H2O Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 Tidal Volume: 6 mL/kg Zero inspiratory pause Respiratory frequency will be adapted to produce an End-Tidal CO2 35-40 mmHg
Study NCT02966665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximum Exercise Tests
Description: Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.
Study NCT00976261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1614235
Description: Glucose lowering in Type 2 Diabetes Mellitus
Study NCT00976261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Glucose lowering in Type 2 Diabetes Mellitus
Study NCT00976261 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator
Study NCT03278925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT03278925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT03278925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03278925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defined Green Tea Catechin Extract
Description: Given PO
Study NCT03278925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03278925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03278925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03278925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03278925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound
Study NCT04144062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM crowns
Description: CAD/CAM crowns
Study NCT00985140 — intervention group
Intervention type: RADIATION
Intervention: Total Skin Electron Beam Therapy (TSEBT)
Description: The purpose of the study is to examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gray) in patients who have mycosis fungoides (MF) staged as IB to IIIB.
Study NCT02557815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus
Study NCT02557815 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus
Study NCT02630485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graceful Lifestyle Changes
Description: Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.
Study NCT02630485 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.
Study NCT02630485 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Myo-inositol
Description: Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.
Study NCT02630485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
Study NCT00981292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EGCG
Description: Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.
Study NCT00981292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG
Description: Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.
Study NCT03873233 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Evone ventilator and Tritube
Description: Fraction of Inspired Oxygen (FIO2) 0.3 Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 End Expiratory Pressure (EEP) at +5 cm H2O Flow: start with 10 L/min and adjusted along with the peak inspiratory pressure to produce a tidal volume of 6 mL/kg and End-Tidal CO2 35-40 mmHg
Study NCT00107471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given PO
Study NCT00107471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00107471 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00981292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical grade silica was utilized as placebo
Study NCT00981292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical grade silica was utilized as placebo
Study NCT04295668 — intervention group
Intervention type: BEHAVIORAL
Intervention: Usual care
Description: The preoperative standard measures consist of physical activity recommendation and advice on both smoking cessation and alcohol intake reduction. Moreover, in patients presenting with anemia, the anesthesiologists will assess its etiology and treat it accordingly, and nutritional intervention will be performed by a registered dietitian in to those patients at risk of malnutrition (Malnutrition Universal Screening Tool ≥2).
Study NCT04295668 — intervention group
Intervention type: BEHAVIORAL
Intervention: Prehabilitation
Description: i) Exercise training: Ambulatory exercise training sessions with two main components, namely: high-intensity endurance exercise training and strength muscular training.~ii) Promotion of physical activity: Pedometer-based program using a physical activity tracker linked to a mobile app.~iv) Nutritional optimization: Recommendations of a healthy balanced diet or adapted to their digestive symptoms. Daily amount of protein intake will be close to 2 g•Kg-1•day-1.~iv) Smoking cessation: Use of both cognitive behavioral intervention and pharmacological therapy by varenicline or nicotine replacement therapies.~v) Cognitive behavioral therapy: Weekly group sessions conducted by a clinical health psychologist, including psychoeducation, motivational and behavioral change, self-efficacy and adherence enhancement, coping strategies acquisition and patient empowerment.
Study NCT04527666 — intervention group
Intervention type: DRUG
Intervention: Anticoagulation Agents
Description: Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.
Study NCT04285177 — intervention group
Intervention type: PROCEDURE
Intervention: Strabismus surgery
Description: Resection or recession of the medial or lateral rectus muscle, or inferior oblique myectomy
Study NCT01814189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sumatriptan+Promethazine (SPr)
Study NCT01814189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan+Promethazine (SPr)
Study NCT02484040 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Two-week course of radiation
Description: 33 Gy in 10 fractions for 2 weeks
Study NCT02484040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two-week course of radiation
Description: oral capecitabine, 825mg/m2, bid
Study NCT02311582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: -Patients currently on pembrolizumab beyond the 2 year/35 cycle limit at the time of the approval of Amendment 13 (approved 07/28/2021) may continue to receive pembrolizumab unless there is progression, toxicity or agreement by the patient and PI to come off therapy. Participants who discontinue pembrolizumab after receiving 35 doses are eligible for retreatment with pembrolizumab if they progress during follow-up provided they meet the requirements. Participants may receive an additional 17 cycles (12 months) of pembrolizumab during the Second Course Phase (Retreatment).
Study NCT02311582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided laser ablation
Study NCT02311582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection/debulking
Description: * Optional~* Standard of care
Study NCT02311582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: * If no surgical resection/debulking~* Phase II patients only
Study NCT02311582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw for research purposes
Description: * Phase II patients only~* Drawn prior to MLA or biopsy/surgical resection procedure, and immediately prior to each the first dose of MK-3475. Subsequently, research blood will be drawn at doses 2, 4, 6, 9, 18, 36, and at the end of treatment
Study NCT04488991 — intervention group
Intervention type: OTHER
Intervention: Cervical Cancer Rate
Description: In the end of the Research, we will compare cervical cancer rates between groups
Study NCT02311582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical lymph node fine needle aspiration
Description: * Optional~* Time of surgical procedure and 6 weeks +/- 1 week after surgical procedure
Study NCT04847505 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-TATE
Description: The intervention consists of an intravenous injection of the radiopharmaceutical 68Ga-DOTA-TATE and a physiological saline flush, followed 45-90 minutes later by a PET/CT image acquisition.
Study NCT00952679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast Lesion Localization Needles (interv)
Description: needles to locate sln in CT monitor guided by CT
Study NCT02760199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-AMG211
Description: Injection of 89Zr-AMG211 for imaging.
Study NCT02760199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 89-ZrAMG211 PET
Description: 89Zr-AMG211 PET scan(s).
Study NCT01250405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet
Description: One sequence receives Cinacalcet 30mg /d for 7 days followed by placebo for 7 days
Study NCT01250405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days
Study NCT03833349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinning Class
Description: Spinning Class twice a week for six weeks.
Study NCT03833349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Class
Description: Yoga Class twice a week for six weeks.
Study NCT03833349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Class
Description: Dance Class twice a week for six weeks.
Study NCT04142762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158
Description: ABI-H2158 tablets
Study NCT04142762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole capsules
Study NCT04142762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin capsules
Study NCT04142762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup
Study NCT04142762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol / Levonorgestrel
Description: Ethinyl Estradiol / Levonorgestrel tablets
Study NCT04142762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole capsules
Study NCT04142762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching oral contraceptive
Description: Placebo matching Ethinyl Estradiol / Levonorgestrel tablets
Study NCT04114773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCARF (Survivors of Cardiac Arrest Rehabilitation focused on Fatigue)
Description: The intervention will be delivered by a multidisciplinary team. There will be individual testing and feedback on physical capacity and cognitive ability. Group sessions will include education on the consequences of cardiac arrest, promotion of techniques to ameliorate these consequences, for example, increasing physical activity or energy conservation. Additional sessions will cover psychological reactions; family life; work life; intimacy; and existential considerations.~Participants will have a course information book with a physical activity training diary and problem-solving therapy worksheets to use at home for 12-weeks. They will receive one phone call from the clinical team during this period. The 2-day return stay will revisit the subjects from the first 5-day stay.~Participating survivors who have a relative that wishes to attend will be included in all the group sessions and individual feedback but will not take part in the physical capacity or cognitive ability tests.
Study NCT01524809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
Study NCT01524809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
Study NCT03491852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOOST Intervention
Description: A cognitive and behavioural group therapy designed to reduce self-stigma and promote effective communication skills for adults (16-65 years old) experiencing a first episode of psychosis.
Study NCT03491852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis.
Study NCT00628134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calfactant
Description: single inhaled dose by nebulizer
Study NCT00628134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotonic saline
Description: single inhaled dose by nebulizer
Study NCT01269827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Over a period of 4 months, patients of the study group received one PTX tablet (400 mg) orally once a day (at dinner time)
Study NCT01269827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: starch tablets
Description: Over a period of 4 months, patients of the control group received one starch tablet orally once a day (at dinner time)
Study NCT00740428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pregnants for receive the physical therapy guide
Description: pregnants for the first time who will receive the physical therapy guide, perform the exercises under the supervision of a physical therapist, and complete an exercise compliance form and a log with information on urinary losses.
Study NCT02871791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Study NCT02871791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT02871791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Study NCT02098148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Study NCT02098148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT05103995 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention, just observation
Study NCT00608491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stepped pharmacologic care
Description: Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
Study NCT00608491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Description: All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
Study NCT02705352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Treatment medication
Study NCT02705352 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study NCT01619527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat
Study NCT01619527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobicistat
Description: Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir